Related references
Note: Only part of the references are listed.Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)
Seema A. Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Role of ctDNA in Breast Cancer
Marta Sant et al.
CANCERS (2022)
Clinical Review on the Management of Hormone Receptor-Positive Metastatic Breast Cancer
Nicholas P. McAndrew et al.
JCO ONCOLOGY PRACTICE (2022)
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
J. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study
Atilla Soran et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Surgery for primary tumor benefits survival for breast cancer patients with bone metastases: a large cohort retrospective study
Zhangheng Huang et al.
BMC CANCER (2021)
The Exciting New Field of HER2-Low Breast Cancer Treatment
Daniel Eiger et al.
CANCERS (2021)
Breast cancer patients with isolated bone metastases and oligometastatic bone disease show different survival outcomes
Baha Zengel et al.
SCIENTIFIC REPORTS (2021)
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis
Daniel Reinhorn et al.
BREAST (2021)
Primary Surgery with Systemic Therapy in Patients with de Novo Stage IV Breast Cancer: 10-year Follow-up; Protocol MF07-01 Randomized Clinical Trial
Atilla Soran et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2021)
Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA)
David Krug et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2021)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Oligometastatic Breast Cancer: Is This a Curable Entity? A Contemporary Review of the Literature
Igor Makhlin et al.
CURRENT ONCOLOGY REPORTS (2020)
Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis
Ritika Gera et al.
SCIENTIFIC REPORTS (2020)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2020)
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A. Palma et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
Yolande Lievens et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Michela Piezzo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review
Oraianthi Fiste et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
Massimo Cristofanilli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: A real-world observational study
Kang Wang et al.
EJSO (2019)
Surgery and survival in patients with stage IV breast cancer
Cletus Arciero et al.
BREAST JOURNAL (2019)
Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis
Elvire Pons-Tostivint et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01
Atilla Soran et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer
Anuhya Kommalapati et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Primary tumor resection in metastatic breast cancer: A propensity-matched analysis, 1988-2011 SEER data base
Nasreen A. Vohra et al.
BREAST JOURNAL (2018)
The immune system in cancer metastasis: friend or foe?
Louise M. E. Janssen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Surgery for Cancer: A Trigger for Metastases
Samer Tohme et al.
CANCER RESEARCH (2017)
Hormone receptor status may impact the survival benefit of surgery in stage iv breast cancer: a population-based study
Yinuo Tan et al.
ONCOTARGET (2016)
Initial Surgery and Survival in Stage IV Breast Cancer in the United States, 1988-2011
Alexandra Thomas et al.
JAMA SURGERY (2016)
Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial
Rajendra Badwe et al.
LANCET ONCOLOGY (2015)
Primary Tumor Extirpation in Breast Cancer Patients Who Present with Stage IV Disease is Associated with Improved Survival
Julie E. Lang et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden
Omar M. Rashid et al.
SURGERY (2013)
Locoregional therapy in luminal-like and HER2-enriched patients with de novo stage IV breast cancer
Peng-Yu Chen et al.
SPRINGERPLUS (2013)
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials
LANCET (2011)
Stage IV Breast Cancer in the Era of Targeted Therapy Does Surgery of the Primary Tumor Matter?
Heather B. Neuman et al.
CANCER (2010)
Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models
Huiping Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival
Andrea C. Bafford et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Association of surgery with improved survival in stage IV breast cancer patients
D. Kay Blanchard et al.
ANNALS OF SURGERY (2008)
Matched Pair Analyses of Stage IV Breast Cancer with or Without Resection of Primary Breast Site
B. Cady et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Primary tumor resection in stage IV breast cancer: Consistent benefit, or consistent bias?
Seema A. Khan
ANNALS OF SURGICAL ONCOLOGY (2007)
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Antoine E. Karnoub et al.
NATURE (2007)
Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: Analysis of the 1988-2003 SEER data
Jennifer Gnerlich et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Extending survival with chemotherapy in metastatic breast cancer
J O'Shaughnessy
ONCOLOGIST (2005)
Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease
EA Danna et al.
CANCER RESEARCH (2004)
Does aggressive local therapy improve survival in metastatic breast cancer?
SA Khan et al.
SURGERY (2002)
Share Paper
